Kymera Therapeutics
KYMR
#3730
Rank
โ‚น229.37 B
Marketcap
โ‚น3,542
Share price
-8.67%
Change (1 day)
135.93%
Change (1 year)

P/E ratio for Kymera Therapeutics (KYMR)

P/E ratio as of November 2024 (TTM): -15.0

According to Kymera Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -14.9826. At the end of 2022 the company had a P/E ratio of -8.67.

P/E ratio history for Kymera Therapeutics from 2020 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-8.67-71.88%
2021-30.8-16.63%
2020-37.0

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
-3.79-74.68%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.